In one now UPDATED and handy table, as I'd earlier detailed, below are some of the larger Schering-Plough franchises with looming near-term "in substance" patent cliffs:
| Branded Name | Sales ($M/Yr) | Compound Name | First Suit Filed | 30 Month Expiry/ "At Risk" Date | Likely Competitor |
| Zetia® | $900 Million | Ezetimibe | March 2007 | October 2009* | Glenmark Pharma |
| Temodar® | $950 Million | Temozolomide | July 2007 | January 2010 | Barr Labs (Teva Pharma) |
| Integrilin® | $300 Million | Eptifibatide | February 2009 | November 2011 | Teva Pharma |
| Levitra® | $430 Million | Vardenafil HCl | July 2009 | April 2012 | Teva Pharma |
| Clarinex® | $800 Million | Descloratadine | September 2006 | July 2012** | Orchid Pharma |
| Total: | $3.38 Billion | .. | .. | .. | .. |
~~~~~~~~~~~~~
* Trial could begin by year end 2009; though admittedly unlikely, an "at risk" launch (by Glenmark, most likely) "window" will be open -- and could occur at any time -- beginning in October 2009.
** All potential generic descloratadine manufacturers have agreed to a launch suspension until at least January 2012 (Orchid -- the one most likely to launch -- will wait, per agreement, until July 2012), though the permissive "at-risk" launch window first-opened in July of 2009.
~~~~~~~~~~~~~
No comments:
Post a Comment